--- title: Consultation on Proposals for the Future of UK Clinical Trial Legislation description: Broughton's Head of Regulatory Affairs, Lloyd Smart, discusses the consultation on proposals for the future of UK clinical trial legislation and highlights selected legislative changes. image: https://www.broughton-group.com/hubfs/iStock-1136432871%20(1).jpg --- # Consultation on Proposals for the Future of UK Clinical Trial Legislation ### Pharmaceuticals ![](https://www.broughton-group.com/hubfs/iStock-1136432871%20(1).jpg) Mar 2, 2022 | Published by  [ Lloyd Smart ](https://www.broughton-group.com/blog/author/lloyd-smart) Pharmaceuticals **Broughton's Head of Regulatory Affairs, Lloyd Smart, has recently published an article with the leading sector publication, PharmTech.**   The Medicines and Healthcare products Regulatory Agency (MHRA) is playing a fundamental role in ensuring that the United Kingdom remains one of the best places in the world to research and develop safe and innovative medicines. In August 2021, as part of a wider piece of work around clinical trials in the UK, MHRA launched new systems functionality to support the combined review of Clinical Trials of Investigational Medicinal Products (CTIMPs). ### Highlights of selected legislative changes In this article, Lloyd discusses the consultation on proposals for the future of UK clinical trial legislation and highlights selected legislative changes. To simplify and streamline applications, MHRA proposes a range of changes including: - amendments in the request for information (RFI) process - introduction of a notification scheme for low-intervention trials - updated requirements for research ethics committees - certain UK definitions The article is available to read [here.](https://www.pharmtech.com/view/consultation-on-proposals-for-the-future-of-uk-clinical-trial-legislation)   To identify your next steps, contact us to [book a meeting](https://www.broughton-ns.com/contact-us) with our regulatory services team. If you’d like to learn more about regulatory pathways and how they create new business opportunities for forward-looking companies then read our recent Regulatory Digest below: [![New call-to-action](https://no-cache.hubspot.com/cta/default/4940960/7079240f-ce72-46cf-8e9b-0171997c0966.png)](https://cta-redirect.hubspot.com/cta/redirect/4940960/7079240f-ce72-46cf-8e9b-0171997c0966) ### Can we help you? **Broughton have deep CRO capabilities and an experienced team of scientific and regulatory professionals to manage full service global regulatory projects. Our knowledge of global regulatory pathways offers significant insights that can be incorporated into your project plans. Our mission is to accelerate safer nicotine-delivery products to market; creating a smoke-free future.** [**Book a meeting**](https://www.broughton-ns.com/contact-us)** with us today to discuss your requirements.**     ### Sign up to our newsletter Ensure your business stays ahead of the competition by keeping up to date with the latest industry news. Sign-up for our newsletter to have the latest information and insights served directly to your inbox. ### Related posts [View all](https://www.broughton-group.com/blog/) [![](https://www.broughton-group.com/hs-fs/hubfs/iStock-1278926982.jpg?height=200&name=iStock-1278926982.jpg) ](https://www.broughton-group.com/blog/us-congress-set-to-close-the-loophole-on-the-use-of-synthetic-nicotine-in-electronic-nicotine-delivery-systems-ends) [**Nicotine**](https://www.broughton-group.com/blog/tag/nicotine) 2 minute read ### [US Congress set to close the loophole on the use of synthetic nicotine in Electronic Nicotine Delivery Systems (ENDS)](https://www.broughton-group.com/blog/us-congress-set-to-close-the-loophole-on-the-use-of-synthetic-nicotine-in-electronic-nicotine-delivery-systems-ends) Broughton's Chief Commercial Officer, Andy Mooney, discusses the latest synthetic nicotine legislation and what this means for ENDS manufacturers. [![](https://www.broughton-group.com/hs-fs/hubfs/Cannabis%20Plants.jpg?height=200&name=Cannabis%20Plants.jpg) ](https://www.broughton-group.com/blog/understanding-the-cannabinoid-regulatory-landscape-in-the-uk) [**Cannabinoids**](https://www.broughton-group.com/blog/tag/cannabinoids) 2 minute read ### [Understanding the cannabinoid regulatory landscape in the UK](https://www.broughton-group.com/blog/understanding-the-cannabinoid-regulatory-landscape-in-the-uk) Broughton Principal Scientist, Paul Barr, has written a white paper outlining the current legislation and regulatory landscape within the cannabinoid market in the United Kingdom (UK). [![](https://www.broughton-group.com/hs-fs/hubfs/iStock-1415564652.jpg?height=200&name=iStock-1415564652.jpg) ](https://www.broughton-group.com/blog/supporting-next-gen-nicotine-compliance-through-vapril) [**Nicotine**](https://www.broughton-group.com/blog/tag/nicotine) 2 minute read ### [Supporting next-gen nicotine compliance through VApril](https://www.broughton-group.com/blog/supporting-next-gen-nicotine-compliance-through-vapril) Smoking costs the UK economy and wider society £17 billion a year, costing the NHS and social care £3 billion, and cigarettes are responsible for 64,000 deaths a year in England alone, according to...